VALZ‐Pilot: High‐dose valacyclovir treatment in patients with early‐stage Alzheimer's disease

VALZ‐Pilot: High‐dose valacyclovir treatment in patients with early‐stage Alzheimer's disease

Abstract Introduction Herpes simplex virus (HSV) may be involved in Alzheimer's disease (AD) pathophysiology. The antiviral valacyclovir inhibits HSV replication. Methods This phase‐II pilot trial involved valacyclovir administration (thrice daily, 500 mg week 1, 1000 mg weeks 2–4) to persons a...

Full description

Bibliographic Details
Main Authors: Bodil Weidung, Eva‐Stina Hemmingsson, Jan Olsson, Torbjörn Sundström, Kaj Blennow, Henrik Zetterberg, Martin Ingelsson, Fredrik Elgh, Hugo Lövheim
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
Alzheimer's disease
apolipoprotein E ε4
feasibility study
herpes simplex
pilot project
valacyclovir
Online Access:https://doi.org/10.1002/trc2.12264

Internet

https://doi.org/10.1002/trc2.12264

Similar Items